October is Breast Cancer Awareness Month, and this Saturday, WABC-TV will air a special feature, “Breast Cancer: Second Chances & New Advances” at 7:30PM. Hosted by Eyewitness News Anchor, Diana Williams, the breast cancer special highlights new advances that are helping those who are newly diagnosed or dealing with a recurrence.
While scientists work on the search for a cure, exciting progress has been made for those dealing with the worst form of breast cancer, triple negative breast cancer (TNBC). Dr. Linda Vahdat from the Weill Cornell Breast Center and NewYork-Presbyterian Hospital talks about the effects of copper depletion in the body. In addition to hearing about promising clinical trial results, hear from participating survivors who are living proof of the progress being made in the fight against TNBC, with hopes of FDA approval in the near future.
Additionally, doctors and researchers from other area medical centers share the latest on breast conservation for patients who have had a recurrence and new advances in immunotherapy offering targeted treatments for survivors.
This annual special is part of WABC-TV’s commitment to the American Cancer Society’s Making Strides Against Breast Cancer campaign. Learn more.
Dr. Linda Vahdat is seeking women 18 years of age or older, diagnosed with metastatic triple negative breast cancer for a research study.
This clinical trial is for women with metastatic triple negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
To learn more about the study and to see if you are eligible [go]
Dr. Linda Vahdat is seeking volunteers for a new research study in triple negative breast cancer.
This clinical trial is for women with metastatic triple-negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.
The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (“eribulin”) in combination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer.
For more information visit our website
You can also find us on Twitter and Facebook
We are excited to announce the Weill Cornell Medical College Breast Center’s contributions to the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting next week!
Dr. Eleni Nackos (on behalf of Dr. Linda Vahdat) will be giving an oral presentation on the results from our phase 2 tetrathiomolybdate (TM) study. http://abstracts.asco.org/156/AbstView_156_151971.html
Dr. Tessa Cigler is chairing the Patient and Survivor Care session. Our abstract on cold caps was selected for a poster discussion session. http://abstracts.asco.org/156/AbstView_156_149240.html
Dr. Eleni Andreopoulou was selected by the International Development and Education Award (IDEA) group to mentor a physician from Morocco. Oncologists are selected by this group to host recipients for three-day visits following the ASCO meeting.
“The purpose of the IDEA program is to support the professional development of early-career oncologists in low- and middle-income countries around the world. The program pairs IDEA recipients with ASCO members in the United States or Canada who serve as their scientific mentors. Upon the mentees’ return to their home institution, it is expected that mentors and mentees remain in contact and pursue opportunities for consultation and collaboration.”
Dr. Anne Moore is chairing the Leadership Development Program presentation to the ASCO Board of Directors. The Leadership Development Program is a year-long program to learn leadership skills, gain exposure to the roles and mission of ASCO, and developing the future of cancer care. Dr. Moore is also joining the IDEA Working Group.
To view other abstracts from our studies:
PARP inhibitor ABT-888 http://abstracts.asco.org/156/AbstView_156_144933.html
Ovarian reserve and menses http://abstracts.asco.org/156/AbstView_156_147965.html
The METRIC study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150265.html
IMMU study for metastatic triple negative breast cancer: http://abstracts.asco.org/156/AbstView_156_150673.html
Please find us on Twitter @CornellBreastCr & Facebook Weill Cornell Breast Center